FDA approves antidepressant nasal spray

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Approval of Spravato, granted following FDA priority review, was based on the results of ... compared with 7.6% of patients ...
The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
As major U.S. indexes like the Dow Jones, S&P 500, and Nasdaq Composite are on track for gains amid positive earnings reports and stable inflation data, investors continue to navigate a landscape ...
The following school districts have scheduled closures and delayed starts on Friday, Jan. 31 as a result of storm-related wintry conditions:Westchester CountyBedford Central School District, ...
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to ...